UTI vaccine
A UTI vaccine is a vaccine used for prevention of urinary tract infections (UTIs).[1][2] A number of UTI vaccines have been developed and/or marketed, including Uromune (MV-140), UroVaxom (OM-89), Solco-Urovac, and ExPEC4 V.[1][2]
Background Information about UTI[edit]
Recurrent urinary tract infections (UTIs) are common in women, causing significant physical and emotional distress. While antibiotics are often the go-to treatment, the recurrence of UTIs poses a significant challenge. Long-term antibiotic use not only poses health risks but also contributes to the growing problem of antibiotic resistance, making effective treatment more challenging. In light of these challenges, the search for an efficient solution continues.
Vaccine Solution: MV140[edit]
Therefore, an efficient solution is still on the search but there has been a potential candidate. There are studies being made on creating a UTI vaccine with MV140, also known as Uromune®. It is a vaccine made from heat-inactivated bacteria mixed with in glycerol, sodium chloride, artificial pineapple flavoring, and water (Nickel 2023). It contains specific strains of four types of bacteria: Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus vulgaris.
This vaccine is taken by spraying it under the tongue twice a day for three months. It's designed to prevent recurrent urinary tract infections (UTIs) and is currently being tested in clinical trials. Studies suggest that MV140 works by stimulating the immune system to produce antibodies and activate certain immune cells, which help protect against UTIs.
Study[edit]
In a conducted study, it involving 89 individuals with a history of urinary tract infections (UTIs), participants were instructed to use two sprays of the vaccine daily for three months. Preliminary results presented at the European Association of Urology Congress in Paris revealed that nine years later, 54 percent of the participants remained free from UTIs. Women in the study remained UTI-free for approximately 4.5 years on average, while men experienced around 3.5 years without UTIs (Rapaport 2024). Dr. Bob Yang, who co-led the study and serves as a consultant urologist at the Royal Berkshire NHS Foundation Trust in the United Kingdom, noted that before receiving the vaccine, all participants had struggled with recurrent UTIs, which can be challenging to treat.
Current Limitation[edit]
While the potential of MV140 is promising, its widespread availability hinges on regulatory approval. Currently, the vaccine remains in the experimental stage and waits approval from the U.S. Food and Drug Administration (FDA). This delay poses a significant barrier for patients in the United States, who are eagerly awaiting alternative solutions to recurrent UTIs.
Healthy Lifestyle Measures to Prevent UTI[edit]
As we anticipate the arrival of this new vaccine, it is crucial to consider current preventive measures. Simple lifestyle changes, such as staying hydrated, practicing good hygiene, and avoiding irritants like certain contraceptives and fragranced products, can help reduce UTI risk. Additionally, cranberry supplements or probiotics may offer some protection against UTIs. Although these small measures might not as powerful as a vaccine, they still play a vital role in mitigating UTI recurrence.
Conclusion[edit]
In conclusion, The MV140 vaccine presents a great source for prevent recurrent UTIs as it offers hope for those burdened by this common yet debilitating infection. Continued research and development in the field of UTI prevention are essential to benefit those in needs. Until a more effective treatment becomes widely available, a combination of lifestyle modifications and existing preventive measures are here to help.
References[edit]
- ^ a b Nickel JC, Saz-Leal P, Doiron RC (August 2020). "Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future". Can Urol Assoc J. 14 (8): 281–287. doi:10.5489/cuaj.6690. PMC 7402698. PMID 33626320.
- ^ a b Prattley S, Geraghty R, Moore M, Somani BK (May 2020). "Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review". Eur Urol Focus. 6 (3): 593–604. doi:10.1016/j.euf.2019.11.002. PMID 31806578.
Nickel, J Curtis, and R Christopher Doiron. “An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women.” Pathogens (Basel, Switzerland), U.S. National Library of Medicine, 21 Feb. 2023, www.ncbi.nlm.nih.gov/pmc/articles/PMC10052183/. Rapaport, Lisa, et al. “Experimental Uti Vaccine Offers Potential Alternative to Antibiotics.” EverydayHealth.Com, www.everydayhealth.com/urinary-tract-infection/new-uti-vaccine-is-a-mouth-spray-that-tastes-like-pineapple/. Accessed 6 May 2024.
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |